ALVO OAKTREE ACQUISITION CORP II

Granting of Stock Options and Vesting of Restricted Share Units

Granting of Stock Options and Vesting of Restricted Share Units

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.

The aim of the stock option grants is to align the long-term interests of the board members and the Company. The relevant key terms and conditions of the Company´s Equity Incentive Plan approved by Alvotech’s Annual and Extraordinary General Meeting on June 13, 2022 are as follows:

  • The stock option agreements entitle the grantee to purchase Alvotech shares at an exercise price of USD 9.28 per share*.
  • The options are subject to a vesting period over three years with yearly vesting, i.e. one third of the options vest each year starting on the AGM where the stock options were awarded.  
  • The options are only exercisable if the grantee is still a member of the board of Alvotech at the time of vesting.

Attached to this announcement are filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) made by the respective four independent board directors of their vested RSUs, in accordance with previous grants.

*The exercise price is determined by the opening price of the Company's ordinary shares on the Nasdaq US stock exchange on the date of the grant, in this case on June 25, 2025. 



Alvotech Investor Relations

Benedikt Stefansson, VP

Attachments



EN
01/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

Alvotech Reports Results for the First Six Months of 2025 and Provides...

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market Conference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT) REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “C...

 PRESS RELEASE

Alvotech Reports Results for the First Six Months of 2025 and Provides...

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for pipeline assetsAlvotech listed on Nasdaq Stockholm MarketConference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT) REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimil...

 PRESS RELEASE

Alvotech birtir uppgjör fyrir fyrstu sex mánuði ársins og kynnir nýjus...

Alvotech birtir uppgjör fyrir fyrstu sex mánuði ársins og kynnir nýjustu áfanga í rekstri félagsins Yfir 200% aukning á tekjum af sölu lyfja á fyrri helmingi ársins miðað við sama tíma í fyrraAnnar ársfjórðungur sá besti í sögu félagsins hvað varðar handbært fé frá rekstri Nýir samningar um markaðsetningu endurspegla virði lyfja á fyrri stigum þróunarBréf Alvotech skráð á Nasdaq markaðinn í StokkhólmiKynning á uppgjörinu í beinu streymi fimmtudaginn 14. ágúst kl. 12 á hádegi (á ensku) REYKJAVIK, 13. ágúst 2025 - Alvotech (NASDAQ: ALVO) birtir í dag uppgjör fyrir fyrstu sex mánuði ársins og...

 PRESS RELEASE

Alvotech Announces Webcast to Report Financial Results for the First H...

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025.  Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, ...

 PRESS RELEASE

Alvotech kynnir uppgjör fyrri helmings ársins 2025 þann 14. ágúst nk. ...

Alvotech kynnir uppgjör fyrri helmings ársins 2025 þann 14. ágúst nk. kl. 12 á hádegi REYKJAVÍK (6. ágúst 2025) Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrri helming ársins 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 13. ágúst nk. Fundur til kynningar á uppgjörinu verður sendur út í beinu streymi og hefst hann kl. 12 á hádegi, fimmtudaginn 14. ágúst nk. Streymi af uppgjörsfundinum, sem fer fram á ensku, verður aðgengilegt á fjárfestasíðu Alvotech, , á slóðinni . Þar verður einnig hægt að finna upptöku af fundinum eftir að honum er lokið, sem aðgengil...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch